Literature DB >> 22101321

Mild cognitive impairment: pathology and mechanisms.

Elliott J Mufson1, Lester Binder, Scott E Counts, Steven T DeKosky, Leyla de Toledo-Morrell, Stephen D Ginsberg, Milos D Ikonomovic, Sylvia E Perez, Stephen W Scheff.   

Abstract

Mild cognitive impairment (MCI) is rapidly becoming one of the most common clinical manifestations affecting the elderly. The pathologic and molecular substrate of people diagnosed with MCI is not well established. Since MCI is a human specific disorder and neither the clinical nor the neuropathological course appears to follow a direct linear path, it is imperative to characterize neuropathology changes in the brains of people who came to autopsy with a well-characterized clinical diagnosis of MCI. Herein, we discuss findings derived from clinical pathologic studies of autopsy cases who died with a clinical diagnosis of MCI. The heterogeneity of clinical MCI imparts significant challenges to any review of this subject. The pathologic substrate of MCI is equally complex and must take into account not only conventional plaque and tangle pathology but also a wide range of cellular, biochemical and molecular deficits, many of which relate to cognitive decline as well as compensatory responses to the progressive disease process. The multifaceted nature of the neuronal disconnection syndrome associated with MCI suggests that there is no single event which precipitates this prodromal stage of AD. In fact, it can be argued that neuronal degeneration initiated at different levels of the central nervous system drives cognitive decline as a final common pathway at this stage of the dementing disease process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101321      PMCID: PMC3282485          DOI: 10.1007/s00401-011-0884-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  186 in total

Review 1.  Mild cognitive impairment clinical trials.

Authors:  Ronald C Petersen
Journal:  Nat Rev Drug Discov       Date:  2003-08       Impact factor: 84.694

2.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

3.  Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia.

Authors:  D R Thal; M Holzer; U Rüb; G Waldmann; S Günzel; D Zedlick; R Schober
Journal:  Exp Neurol       Date:  2000-05       Impact factor: 5.330

4.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

Authors:  A M Cataldo; C M Peterhoff; J C Troncoso; T Gomez-Isla; B T Hyman; R A Nixon
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease.

Authors:  Francisco García-Sierra; Nupur Ghoshal; Bruce Quinn; Robert W Berry; Lester I Binder
Journal:  J Alzheimers Dis       Date:  2003-04       Impact factor: 4.472

6.  Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology.

Authors:  Milos D Ikonomovic; Elliott J Mufson; Joanne Wuu; Elizabeth J Cochran; David A Bennett; Steven T DeKosky
Journal:  J Alzheimers Dis       Date:  2003-02       Impact factor: 4.472

7.  Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1.

Authors:  Oscar L Lopez; William J Jagust; Steven T DeKosky; James T Becker; Annette Fitzpatrick; Corinne Dulberg; John Breitner; Constantine Lyketsos; Beverly Jones; Claudia Kawas; Michelle Carlson; Lewis H Kuller
Journal:  Arch Neurol       Date:  2003-10

8.  Drebrin-dependent actin clustering in dendritic filopodia governs synaptic targeting of postsynaptic density-95 and dendritic spine morphogenesis.

Authors:  Hideto Takahashi; Yuko Sekino; Satoshi Tanaka; Toshiyuki Mizui; Shoji Kishi; Tomoaki Shirao
Journal:  J Neurosci       Date:  2003-07-23       Impact factor: 6.167

9.  Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.

Authors:  Angela L Guillozet; Sandra Weintraub; Deborah C Mash; M Marsel Mesulam
Journal:  Arch Neurol       Date:  2003-05

10.  Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease.

Authors:  Elliott J Mufson; Milos D Ikonomovic; Scot D Styren; Scott E Counts; Joanne Wuu; Sue Leurgans; David A Bennett; Elizabeth J Cochran; Steven T DeKosky
Journal:  Arch Neurol       Date:  2003-08
View more
  76 in total

1.  Automated Multiclass Classification of Spontaneous EEG Activity in Alzheimer's Disease and Mild Cognitive Impairment.

Authors:  Saúl J Ruiz-Gómez; Carlos Gómez; Jesús Poza; Gonzalo C Gutiérrez-Tobal; Miguel A Tola-Arribas; Mónica Cano; Roberto Hornero
Journal:  Entropy (Basel)       Date:  2018-01-09       Impact factor: 2.524

2.  Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability.

Authors:  Bin He; Sylvia E Perez; Sang H Lee; Stephen D Ginsberg; Michael Malek-Ahmadi; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2020-05-05       Impact factor: 3.215

3.  Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease.

Authors:  Elliott J Mufson; Sarah Ward; Lester Binder
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

4.  Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment.

Authors:  Elliott J Mufson; Michael Malek-Ahmadi; Sylvia E Perez; Kewei Chen
Journal:  Neurobiol Aging       Date:  2015-10-20       Impact factor: 4.673

5.  Connectome-scale assessments of structural and functional connectivity in MCI.

Authors:  Dajiang Zhu; Kaiming Li; Douglas P Terry; A Nicholas Puente; Lihong Wang; Dinggang Shen; L Stephen Miller; Tianming Liu
Journal:  Hum Brain Mapp       Date:  2013-09-30       Impact factor: 5.038

6.  Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.

Authors:  Stefan Teipel; Helmut Heinsen; Edson Amaro; Lea T Grinberg; Bernd Krause; Michel Grothe
Journal:  Neurobiol Aging       Date:  2013-10-28       Impact factor: 4.673

7.  Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Authors:  Sylvia E Perez; Bin He; Muhammad Nadeem; Joanne Wuu; Stephen W Scheff; Eric E Abrahamson; Milos D Ikonomovic; Elliott J Mufson
Journal:  Biol Psychiatry       Date:  2014-01-11       Impact factor: 13.382

8.  Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.

Authors:  Elliott J Mufson; Bin He; Muhammad Nadeem; Sylvia E Perez; Scott E Counts; Sue Leurgans; Jason Fritz; James Lah; Stephen D Ginsberg; Joanne Wuu; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

9.  Malignant synaptic growth and Alzheimer's disease.

Authors:  Ehren L Newman; Christopher F Shay; Michael E Hasselmo
Journal:  Future Neurol       Date:  2012-09

Review 10.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.